Similar Items: Five‐year follow‐up of incretin‐based therapy in a patient with KCNJ11‐related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction
- Adaptive islet biology and comprehensive incretin physiology: Emerging perspectives from Asia and Europe
- Real‐World vs. Randomized Trial Evidence for Incretin‐Based Therapies: A Narrative Review
- c‐Jun N‐terminal kinase 3 as a permissive regulator of β‐cell incretin responsiveness
- Recent advances in incretin biology and therapeutics: From glucose‐dependent insulinotropic polypeptide reappraisal to next‐generation agonists
- Successful Topical Treatment of Hydroxyurea-Induced Ulcers Without Drug Discontinuation: A Case Report
- Insulin‐reducing effect of adding imeglimin to ongoing dipeptidyl peptidase‐4 inhibitor therapy with multiple daily insulin injections (INSPIRE study)